AstraZeneca Faces US Regulatory Setback Following Strong Q1 Results

Key Facts

AstraZeneca faced a regulatory hurdle after an FDA expert panel voted against backing a new breast cancer drug, tempering the momentum from its strong first-quarter performance. The company reported a 13% year-over-year increase in revenue to $15.3 billion, driven by robust sales in its oncology and rare-disease portfolios. Alongside these earnings, AstraZeneca announced a $405 million investment in Britain, signaling a strategic return to capital spending in the region. Despite the US regulatory setback, the outlook remains supported by more than 20 upcoming Phase III clinical trial readouts expected to act as major catalysts. The company maintained its full-year 2026 guidance, forecasting revenue growth in the mid-to-high single digits. Investors are now closely monitoring these clinical milestones, as the oncology pipeline remains a core pillar of AstraZeneca's long-term growth strategy.

Version History